Login to Your Account



VEN 309 Phase III Failure Drags Ventrus Down 59%

By Marie Powers
Staff Writer

Tuesday, June 26, 2012

A month after efficacy findings from a pivotal Phase III study of VEN 307 (diltiazem hydrochloride cream) in anal fissures drove share prices higher, Ventrus Biosciences Inc. faced the market's wrath after its randomized, double-blind, placebo-controlled Phase III trial of VEN 309 (iferanserin ointment) failed in hemorrhoidal disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription